Literature DB >> 17619996

Blood-brain barrier transport of therapeutics via receptor-mediation.

Angela R Jones1, Eric V Shusta.   

Abstract

Drug delivery to the brain is hindered by the presence of the blood-brain barrier (BBB). Although the BBB restricts the passage of many substances, it is actually selectively permeable to nutrients necessary for healthy brain function. To accomplish the task of nutrient transport, the brain endothelium is endowed with a diverse collection of molecular transport systems. One such class of transport system, known as a receptor-mediated transcytosis (RMT), employs the vesicular trafficking machinery of the endothelium to transport substrates between blood and brain. If appropriately targeted, RMT systems can also be used to shuttle a wide range of therapeutics into the brain in a noninvasive manner. Over the last decade, there have been significant developments in the arena of RMT-based brain drug transport, and this review will focus on those approaches that have been validated in an in vivo setting.

Mesh:

Substances:

Year:  2007        PMID: 17619996      PMCID: PMC2685177          DOI: 10.1007/s11095-007-9379-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  97 in total

1.  Vector-mediated drug delivery to the brain.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

Review 2.  Molecular and cellular mechanisms of receptor-mediated endocytosis.

Authors:  V I Brown; M I Greene
Journal:  DNA Cell Biol       Date:  1991 Jul-Aug       Impact factor: 3.311

3.  Basic fibroblast growth factor promotes in vivo cerebral angiogenesis in chronic forebrain ischemia.

Authors:  M K Lyons; R E Anderson; F B Meyer
Journal:  Brain Res       Date:  1991-09-06       Impact factor: 3.252

4.  Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.

Authors:  D Wu; J Yang; W M Pardridge
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

5.  Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis.

Authors:  Karim Benchenane; Vincent Berezowski; Carine Ali; Mónica Fernández-Monreal; José P López-Atalaya; Julien Brillault; Julien Chuquet; André Nouvelot; Eric T MacKenzie; Guojun Bu; Roméo Cecchelli; Omar Touzani; Denis Vivien
Journal:  Circulation       Date:  2005-04-25       Impact factor: 29.690

6.  Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes.

Authors:  N Shi; R J Boado; W M Pardridge
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

7.  Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.

Authors:  Jörg Kreuter; Dmitry Shamenkov; Valery Petrov; Peter Ramge; Klaus Cychutek; Claudia Koch-Brandt; Renad Alyautdin
Journal:  J Drug Target       Date:  2002-06       Impact factor: 5.121

Review 8.  Tyrosine hydroxylase and Parkinson's disease.

Authors:  J Haavik; K Toska
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

9.  Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.

Authors:  J H Kordower; V Charles; R Bayer; R T Bartus; S Putney; L R Walus; P M Friden
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

10.  Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.

Authors:  P Anderson; M E Pichichero; R A Insel
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

View more
  125 in total

1.  Transferrin antibodies into the brain.

Authors:  Mark S Dennis; Ryan J Watts
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 2.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

3.  CRM197-induced blood-brain barrier permeability increase is mediated by upregulation of caveolin-1 protein.

Authors:  Ping Wang; Yunhui Liu; Xiuli Shang; Yixue Xue
Journal:  J Mol Neurosci       Date:  2010-11-16       Impact factor: 3.444

4.  A novel vascular targeting strategy for brain-derived endothelial cells using a TCR mimic antibody.

Authors:  Raktima Bhattacharya; Yan Xu; Md Ashequr Rahman; Pierre-Olivier Couraud; Ignacio A Romero; Babette B Weksler; Jon A Weidanz; Ulrich Bickel
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

Review 5.  Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.

Authors:  Linfeng Wu; Xiaoxun Li; Dileep R Janagam; Tao L Lowe
Journal:  Pharm Res       Date:  2013-08-31       Impact factor: 4.200

Review 6.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

7.  Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium.

Authors:  Poornima Kolhar; Aaron C Anselmo; Vivek Gupta; Kapil Pant; Balabhaskar Prabhakarpandian; Erkki Ruoslahti; Samir Mitragotri
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

8.  Creation and Evaluation of a Single-chain Antibody Tetramer that Targets Brain Endothelial Cells.

Authors:  Xiaobin Zhang; Xin Xiang Wang; Eric V Shusta
Journal:  AIChE J       Date:  2014-04-01       Impact factor: 3.993

9.  In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.

Authors:  Carmen Wängler; Dina Nada; Georg Höfner; Simone Maschauer; Björn Wängler; Stephan Schneider; Esther Schirrmacher; Klaus T Wanner; Ralf Schirrmacher; Olaf Prante
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

10.  Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.

Authors:  Son N Nguyen; Cedric E Bobst; Igor A Kaltashov
Journal:  Mol Pharm       Date:  2013-04-10       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.